Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Introduction to Superior Vena Cava (SVC) Syndrome
2008
Author
Howard (Jack) West, MD

Superior vena cava (SVC) syndrome is an infrequent but not rare complication of lung cancer, occurring in 2-4% of cases, most typically an early symptom that leads to the diagnosis. The SVC is the main vein that drains blood back into the heart from the upper body, and it runs in the middle of the chest on the right side, where it is vulnerable to being compressed by a nearby lung cancer or enlarged lymph nodes, such as from lung cancer or lymphoma. Less commonly, SVC syndrome can be caused by a clot within the blood vessel, and it's also possible to have a combination of external compression and blood clot (clots are more likely to develop where blood flow is compromised). This leads to blockage of the blood flow from the upper body and engorged blood vessels and often swelling of the face, neck, and sometimes upper extremities, as shown in this figure (from this summary article): SVC syndrome The leading symptoms of SVC syndrome are facial edema, distended veins in the neck and sometimes chest, arm edema, shortness of breath, cough, facial plethora/fullness, and less commonly wheezing, lightheadedness, headaches, and even confusion.

Although several decades ago infectious issues such as syphylis and TB were common causes of SVC syndrome, it's much more common now to have cancer as a cause today. Specifically, this is usually lung cancer, but lymphoma can also lead to this, and more rarely causes like germ cell tumors in the chest. A few decades ago, cancer was the source of up to 90% of SVC syndromes, but now that indwelling catheters and pacemakers are more common and can lead to clotting within the blood vessels, cancer is the cause in only about 2/3 of cases. The best way to assess this is with a chest CT with intravenous contrast, although ultrasound studies of the upper extremities (OK, arms) can help identify the extent of the backup; MRI scans are also sometimes used, but generally in people who can't receive IV contrast. The diagnosis is made by obtaining tissue, which is sometimes done by draining pleural fluid, since up to 2/3 of patients with SVC syndrome also have a pleural effusion. Whie a thoracentesis (removing fluid around the lung with a needle from the back) is relatively can provide some relief of shortness of breath, it only yields a diagnosis about half of the time. Bronchoscopy works about 50-70% of the time, CT-guided biopsy with a needle from outside of the chest about 75% of the time, and mediastinoscopy somewhere in the range of 90% of the time. Another potential biopsy source would be to excise an enlarged lymph node, such as above the clavicle, which has the advantage of providing a significant amount of tissue to examine. Particularly for lymphoma but also for lung cancer and other malignant causes, haivng more tissue to review is always helpful. Next, we'll turn to management of SVC syndrome.

Next Previous link

Previous PostNext Post

Related Content

Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.
Image
Rare cancers
Video
In these videos,  Dr. Jared Weiss gives a brief overview of NUT Carcinoma, discusses treatment options and possible future treatment.  To watch the complete playlist, click here.  
Article
Don't let the word "small" deceive you. Small cell lung cancer (SCLC) casts a long shadow, impacting lives with its aggressive nature and the complexities of its treatment. But while the challenges are real, so is the progress. Breakthroughs in small cell lung cancer treatment offer hope. Immunotherapy plus chemo-radiation improves survival by 22 months. Screening catches it early.

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Recent Comments

JOIN THE CONVERSATION
Yes, it's crucial to discuss…
By JanineT GRACE … on
Definitely a good idea to…
By OakleeFarnick on
Thank you for sharing
By LeviDrake on
Hi bluesun,I don't know of…
By JanineT GRACE … on